Thermo Fisher Scientific Inc. (NYSE:TMO) Stake Boosted by Roffman Miller Associates Inc. PA

Roffman Miller Associates Inc. PA lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.9% during the 4th quarter, HoldingsChannel.com reports. The fund owned 33,493 shares of the medical research company’s stock after buying an additional 945 shares during the quarter. Roffman Miller Associates Inc. PA’s holdings in Thermo Fisher Scientific were worth $17,778,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Wedge Capital Management L L P NC grew its stake in Thermo Fisher Scientific by 8.3% during the 3rd quarter. Wedge Capital Management L L P NC now owns 740 shares of the medical research company’s stock valued at $375,000 after acquiring an additional 57 shares in the last quarter. Naples Global Advisors LLC increased its stake in Thermo Fisher Scientific by 37.3% in the 3rd quarter. Naples Global Advisors LLC now owns 755 shares of the medical research company’s stock valued at $382,000 after buying an additional 205 shares during the period. Avior Wealth Management LLC boosted its stake in shares of Thermo Fisher Scientific by 41.2% during the 3rd quarter. Avior Wealth Management LLC now owns 3,812 shares of the medical research company’s stock valued at $1,930,000 after buying an additional 1,112 shares during the period. Founders Financial Securities LLC increased its stake in shares of Thermo Fisher Scientific by 10.5% in the third quarter. Founders Financial Securities LLC now owns 1,669 shares of the medical research company’s stock worth $845,000 after acquiring an additional 158 shares during the last quarter. Finally, Meridian Wealth Management LLC boosted its position in Thermo Fisher Scientific by 2.2% during the third quarter. Meridian Wealth Management LLC now owns 2,147 shares of the medical research company’s stock valued at $1,087,000 after purchasing an additional 47 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently weighed in on TMO. Robert W. Baird cut their price objective on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a research report on Thursday. The Goldman Sachs Group increased their price objective on Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Raymond James upped their target price on Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a research report on Thursday, February 1st. JPMorgan Chase & Co. lifted their price target on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research report on Thursday. Finally, Barclays raised their target price on shares of Thermo Fisher Scientific from $590.00 to $615.00 and gave the company an “equal weight” rating in a research note on Thursday. Five equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $606.76.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO traded up $2.99 during midday trading on Friday, reaching $574.72. 704,185 shares of the company traded hands, compared to its average volume of 1,552,624. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.39 and a current ratio of 1.70. The firm has a market cap of $219.38 billion, a PE ratio of 36.70, a PEG ratio of 2.44 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $603.82. The stock’s 50-day simple moving average is $573.08 and its 200-day simple moving average is $529.36.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The business had revenue of $10.35 billion for the quarter, compared to analyst estimates of $10.14 billion. As a group, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were given a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date of this dividend was Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.01%.

Insider Activity at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total value of $5,556,300.00. Following the completion of the transaction, the chief executive officer now owns 49,155 shares of the company’s stock, valued at approximately $27,311,992.65. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total value of $5,556,300.00. Following the completion of the sale, the chief executive officer now directly owns 49,155 shares in the company, valued at $27,311,992.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 5,547 shares of Thermo Fisher Scientific stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $550.62, for a total value of $3,054,289.14. Following the transaction, the chief executive officer now owns 43,608 shares in the company, valued at approximately $24,011,436.96. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 50,277 shares of company stock worth $28,513,384. 0.32% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.